FDA cited South Korea's Cosmo Bio for CGMP failures and for selling an unapproved, misbranded acne drug serum in the U.S.
What happened
The company's facility was registered with FDA as an OTC drug maker, and FDA reviewed records Cosmo Bio submitted after an April 22, 2020 request for records under section 704(a)(4) of the FD&C Act. FDA found no laboratory testing of batches before release, inadequate stability data, and no validated cleaning of shared equipment also used for non-drug products. FDA also found the acne serum is an unapproved new drug and misbranded, and placed the firm on Import Alert 66-40 on September 20, 2021.
What FDA found
The firm did not test each batch in a laboratory before release to confirm it met final specifications, including identity and strength of each active ingredient.
21 CFR 211.165(a)The firm lacked an adequate written stability program and stability data to support the labeled expiry date and storage conditions.
21 CFR 211.166(a)The firm did not validate cleaning of shared equipment that touches product, including equipment also used to make non-drug products.
21 CFR 211.67(b)The acne serum is an unapproved new drug because it is marketed without an FDA-approved application and does not meet the OTC acne monograph.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The product is misbranded because it is a nonprescription drug that does not comply with section 505G and has no approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)The labeling is false or misleading because propolis is featured as if it were an active ingredient but is not listed as one.
FD&C Act section 502(a), 21 U.S.C. 352(a); 21 CFR 201.10(c)(4)
What FDA wants
Cosmo Bio must respond in writing within 15 working days describing what it has done to correct the violations and prevent recurrence. FDA also asked for product specifications and test methods, a plan to test retained samples of U.S. batches within expiry, a stability program overhaul, and cleaning validation procedures.
Who should pay attention
- U.S. brands and retailers selling Korean OTC acne or skin-care products
- importers and distributors of cosmetic-type products that make drug claims
- contract manufacturers that share equipment between drug and non-drug products
This is a summary. Read the original letter on fda.gov.